The CCI (chronic constriction injury) model results in peripheral mononeuropathy, simulating chronic nerve compression in humans. This model is used routinely by the pharmaceutical industry to help guide go/no-go decision making around efficacy, mechanism of action (MoA) and compound development for neuropathic pain indications. In addition, Transpharmation has also developed both diabetic-induced neuropathy (STZ) in collaboration with the University of Hertfordshire and chemotheraphy-induced neuropathy (oxaliplatin) rodent models to evaluate NCEs to treat specifically these increasingly-prevalent chronic conditions. Furthermore, we’ve challenged our understanding beyond traditional end-points, such as allodynia, towards investigating non-evoked clinically relevant behaviours, such as EEG/sleep signatures and cognition disruption (‘chemobrain’).
Examples of the models we offer include:
- CCI (chronic constriction injury) model
- Oxaliplatin chemotherapy-induced neuropathy model
- STZ diabetic-induced neuropathy model
Examples of end points:
- Von Frey hairs (tactile allodynia)
- Hot/cold plate (allodynia)
- LABORAS automated complex behavioural assessment (e.g. locomotor activity)
- EEG/sleep
- Cognition / novel object recognition
- Blood glucose analysis (diabetic-induced neuropathy)
- PK sampling
This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.
